Under this agreement, NetraMark's AI technology will initially be used for Phase 2 (neuroscience and oncology clinical trials) and select Phase 3 clinical trials conducted by Worldwide ...

ConcertAI announced a multi-year agreement with Bayer to leverage ConcertAI's Translational360™ and AI SaaS solutions, which use artificial intelligence and machine learning (AI/ML)-derived insights ...

This agreement unites Worldwide's three decades of clinical execution excellence—recognized with 11 consecutive CRO Leadership Awards—with NetraMark's advanced NetraAI platform, an explainable AI ...

Sol-Gel Technologies secures $16 million for clinical trials, advancing SGT-610 for ... Ltd. has announced a product purchase agreement with Mayne Pharma Group that will provide the company ...